|Bid||79.74 x 800|
|Ask||80.79 x 1200|
|Day's Range||78.76 - 80.17|
|52 Week Range||72.00 - 96.79|
|Beta (5Y Monthly)||0.95|
|PE Ratio (TTM)||42.42|
|Earnings Date||Feb 11, 2020 - Feb 16, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||90.07|
Pharmaceutical executives at the J.P. Morgan Healthcare conference say the industry can fixed pricing problems on its own.
Incyte Corp. will make an upfront payment of $750 million to MorphoSys AG, and purchase another $150 million of stock in the German drug developer, under the terms of a collaboration and licensing agreement the biotech companies signed Monday. The agreement calls for the two companies to work together to further develop and commercialize an xperimental therapy, called tafasitamab, that MorphoSys has had under development for cancers linked to B cell malignancies. The deal, including the equity investment, is subject to government review and must be cleared by U.S., German and Austrian antitrust regulators.
The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.
Incyte Announces the Validation by the EMA of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma
The major stock indexes ended Friday sharply lower after a U.S. airstrike in Iraq. Tesla stock hit a key profit-taking level after strong delivery results.
The stock market rally capped a strong 2019 and kept going in 2020. Tesla stock and Lockheed Martin were big winners. Incyte was among biotech losers.
Incyte stock tumbled to a three-month low Friday amid a flurry of price-target cuts following the biotech company's late-stage failure in never-before-treated acute graft vs. host disease.
Shares of oil producers are up, but stock in airlines is falling. Prices of Treasury debt, a haven investment, have risen.
As shares of Incyte fell about 10.8% in premarket trading on Friday, analysts were divided on whether the trial results were a serious setback for the company.
Dow Jones futures fell as a U.S. airstrike killed a top Iranian general. Apple stock and AMD stock led Thursday's strong start for the 2020 stock market rally.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the ...
U.S. stock futures sink and oil prices surge after a U.S. military strike kills Gen. Qassem Soleimani, a top Iranian general; the U.S. economic calendar includes the ISM Manufacturing Index for December and minutes from the Federal Reserve's Dec. 10-11 meeting; Illumina abandons $1.2 billion acquisition of Pacific Biosciences.
Incyte is cut to neutral from buy at Mizuho Securities USA after a Phase 3 trial of the biotech company's treatment for graft vs. host disease didn't meet its primary endpoint.
Incyte stock crashed late Thursday after the biotech company's treatment for never-before-treated patients with graft vs. host disease, a transplant complication, failed in a study.
Incyte Corp. shares fell more than 12% in after-hours trading Thursday after the company revealed that a phase-3 study of a drug failed to reach its goal. Incyte said that a study seeking to pair itacitinib with corticosteroids to treat a form of graft-versus-host disease, which can strike patients who have had a blood-marrow transplant. The study showed that the treatment was not significantly better than a placebo statistically, the primary endpoint of the study. The key secondary endpoint also was not reached. "The result of this study is disappointing," Incyte Chief Medical Officer Steven Stein said in Thursday's announcement. Incyte's stock closed with a 1.6% decline at $85.97, then plunged to lower than $76 in the extended session after the news was released. Shares have gained 35.3% in the past 12 months, as the S&P 500 index has increased 28.7%.
Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease
Shares of Incyte Corporation fell sharply in late trading Thursday after the company said one of its drugs failed to meet its primary endpoint in a phase 3 trial. The company said its itactinib treatment, in combination with corticosteroids, "did not statistically improve overall response rate or non-relapse mortality" in patients with acute graft-versus-host disease. The disease is commonly seen in patients undergoing bone marrow or organ transplants.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...